About
Exosome Products & Services
Areas of Focus
Categories
Non-PharmaceuticalContract ResearchChina
Clinical Trials (34)
View allTotal Trials
34
As Lead Sponsor
2
As Collaborator
32
Total Enrollment
2,553
By Phase
PHASE1/PHASE2: 4PHASE2: 16PHASE1: 3NA: 3PHASE4: 3PHASE3: 4PHASE2/PHASE3: 1
By Status
COMPLETED: 20TERMINATED: 11NOT_YET_RECRUITING: 1WITHDRAWN: 1UNKNOWN: 1
Clinical Trials Pipeline34 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT07131683Collaborator
hUC-MSC-Exo Therapy for Autoimmune Encephalitis
PHASE1/PHASE2Not yet recruiting
38 participants
Started: Nov 1, 2025 · Completed: Aug 31, 2027
NCT00851552Collaborator
Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment
PHASE2Terminated
9 participants
Started: Jan 31, 2009 · Completed: Sep 30, 2011
NCT00744354Collaborator
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
PHASE1Terminated
32 participants
Started: Oct 31, 2008 · Completed: Apr 30, 2015
NCT00750815Collaborator
Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)
PHASE1/PHASE2Completed
58 participants
Started: Sep 30, 2008 · Completed: May 31, 2013
NCT00570180Collaborator
Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma
PHASE2Completed
36 participants
Started: Aug 25, 2008 · Completed: Sep 15, 2015
Locations (1)
Headquarters
Beijing, China
Map
Loading map...